Bio-Technology General and Serono promote growth:
This article was originally published in Clinica
BioTechnology General is to co-market Serono Laboratories' line of paediatric growth products. This includes Geref Diagnostic, which detects the cause of a child's slow growth and can be used either prior to Geref treatment of idiopathic growth hormone deficiency in children, or as a stand-alone diagnostic agent. Geref, which consists of sermorelin acetate for injection, triggers the release of the body's available reserve of growth hormone. Bio-Technology is based in Iselin, New Jersey, while Serono Laboratories is based in Norwell, Massachusetts.
You may also be interested in...
US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.
Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.
The company has reached a broad opioid settlement agreement in principle under which its specialty generics subsidiaries would file for Chapter 11 bankruptcy and Mallinckrodt's branded business would operate separately.